Surrozen, Inc. (NASDAQ:SRZN) Sees Large Growth in Short Interest

Surrozen, Inc. (NASDAQ:SRZN) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 33,900 shares, a growth of 43.0% from the November 15th total of 23,700 shares. Currently, 1.4% of the shares of the stock are short sold. Based on an average daily volume of 29,300 shares, the days-to-cover ratio is presently 1.2 days.

Surrozen Stock Performance

SRZN traded up $0.14 on Friday, reaching $9.85. The company had a trading volume of 24,834 shares, compared to its average volume of 17,884. The company has a fifty day moving average of $10.29 and a 200-day moving average of $9.75. Surrozen has a one year low of $6.00 and a one year high of $16.19.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.77) by $2.33. The company had revenue of $10.00 million during the quarter. On average, sell-side analysts anticipate that Surrozen will post -7.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Surrozen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CVI Holdings LLC bought a new stake in shares of Surrozen in the 2nd quarter worth $711,000. Stonepine Capital Management LLC acquired a new position in Surrozen during the second quarter worth about $724,000. Nantahala Capital Management LLC bought a new stake in Surrozen in the second quarter worth about $2,050,000. Finally, Armistice Capital LLC acquired a new stake in Surrozen in the 2nd quarter valued at about $2,080,000. 66.57% of the stock is owned by institutional investors.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.